论文部分内容阅读
目的对米非司酮治疗子宫肌瘤的疗效进行探究。方法对130例经B超确诊的子宫肌瘤患者采用口服米非司酮进行治疗,每天1次,每次10毫克,连续服用3个月为1个疗程。比较患者治疗前后的肌瘤体积变化和子宫体积变化,并且监测雄激素(T)、泌乳素(PRL)、孕酮(P)、雌激素(E2)、黄体生成素(LH)、卵泡刺激素(FSH),观察肝肾功能及血尿常规。结果 130例子宫肌瘤患者在治疗过程中均有闭经的出现,与治疗之前相比,肌瘤平均体积和子宫体积明显缩小,差异存在统计学意义;与服药前相比,患者的E2、P、FSH、LH有着显著降低,差异具备统计学意义;与治疗前相比,T、PRL并不存在显著性差异,未出现任何不良反应,并且患者的肝肾功能未出现损伤。结论对于子宫肌瘤的治疗,米非司酮有着突出的疗效,不良反应较小,值得临床应用及推广。
Objective To investigate the efficacy of mifepristone in the treatment of uterine fibroids. Methods One hundred and thirty patients with uterine fibroids diagnosed by B ultrasound were treated with oral mifepristone once a day for 10 mg once daily for 3 months for 1 course of treatment. The changes of fibroids volume and uterine volume before and after treatment were compared. The levels of androgen (T), prolactin (PRL), progesterone (P), estrogen (E2), luteinizing hormone (LH), follicle stimulating hormone (FSH), liver and kidney function and hematuria routine observation. Results All 130 patients with uterine fibroids had amenorrhea in the course of treatment. Compared with that before treatment, the average volume of myoma and the volume of uterine uterus were significantly reduced, with statistical significance. Compared with those before treatment, E2, P , FSH, LH were significantly reduced, the difference was statistically significant; compared with before treatment, T, PRL does not exist significant differences, no adverse reactions, and the patient’s liver and kidney function without damage. Conclusion For the treatment of uterine fibroids, mifepristone has outstanding curative effect with less adverse reactions, which is worthy of clinical application and promotion.